Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 13 points (0.1%) at 18,222 as of Wednesday, Feb. 25, 2015, 12:00 PM ET. The NYSE advances/declines ratio sits at 1,791 issues advancing vs. 1,158 declining with 171 unchanged.

The Health Care sector currently sits up 0.8% versus the S&P 500, which is unchanged. Top gainers within the sector include

Pharmacyclics

(

PCYC

), up 3.0%,

Shire

(

SHPG

), up 2.3%,

Vertex Pharmaceuticals

(

VRTX

), up 1.4%,

Actavis

(

ACT

), up 1.5% and

Allergan

(

AGN

), up 0.8%. On the negative front, top decliners within the sector include

Dr Reddy Laboratories

(

RDY

), down 2.6%,

Valeant Pharmaceuticals International

(

VRX

), down 2.5%,

Mylan

(

MYL

), down 1.9% and

Eli Lilly and

(

LLY

), down 0.7%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3.

Fresenius Medical Care AG & Co. KGaA

(

FMS

) is one of the companies pushing the Health Care sector higher today. As of noon trading, Fresenius Medical Care AG & Co. KGaA is up $2.13 (5.7%) to $39.23 on heavy volume. Thus far, 212,003 shares of Fresenius Medical Care AG & Co. KGaA exchanged hands as compared to its average daily volume of 129,100 shares. The stock has ranged in price between $38.14-$39.78 after having opened the day at $38.15 as compared to the previous trading day's close of $37.10.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides renal dialysis products and services. Fresenius Medical Care AG & Co. KGaA has a market cap of $22.4 billion and is part of the health services industry. Shares are down 0.1% year-to-date as of the close of trading on Tuesday. Currently there are 3 analysts who rate Fresenius Medical Care AG & Co. KGaA a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates

Fresenius Medical Care AG & Co. KGaA

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Fresenius Medical Care AG & Co. KGaA Ratings Report

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading,

Icon

(

ICLR

) is up $6.06 (9.8%) to $67.61 on heavy volume. Thus far, 737,741 shares of Icon exchanged hands as compared to its average daily volume of 387,800 shares. The stock has ranged in price between $63.26-$68.83 after having opened the day at $65.00 as compared to the previous trading day's close of $61.55.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

ICON Public Limited Company, a contract research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, Rest of Europe, the United States, and internationally. Icon has a market cap of $3.8 billion and is part of the health services industry. Shares are up 20.7% year-to-date as of the close of trading on Tuesday. Currently there are 8 analysts who rate Icon a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates

Icon

as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

Icon Ratings Report

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading,

United Therapeutics

(

UTHR

) is up $6.44 (4.2%) to $161.60 on average volume. Thus far, 386,151 shares of United Therapeutics exchanged hands as compared to its average daily volume of 537,200 shares. The stock has ranged in price between $152.44-$162.25 after having opened the day at $156.14 as compared to the previous trading day's close of $155.16.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. United Therapeutics has a market cap of $7.3 billion and is part of the drugs industry. Shares are up 19.8% year-to-date as of the close of trading on Tuesday. Currently there are 3 analysts who rate United Therapeutics a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates

United Therapeutics

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

United Therapeutics Ratings Report

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR

(

XLV

) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care

(

RXD

).

null